TREA

88004821 - M MICROBIX

Follow

Information

  • Trademark
  • 88004821
  • Serial Number
    88004821
  • Registration Number
    7424197
  • Filing Date
    June 18, 2018
    6 years ago
  • Registration Date
    June 25, 2024
    8 months ago
  • Transaction Date
    June 25, 2024
    8 months ago
  • Status Date
    June 25, 2024
    8 months ago
  • Published for Opposition Date
    April 09, 2024
    10 months ago
  • Location Date
    June 24, 2024
    8 months ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    GOODWIN, KATRINA JOYE
  • Attorney Docket Number
    30752/62232
    Attorney Name
    Richard M. LaBarge
  • Owners
Information
Mark Drawing Code
5
Mark Identification
M MICROBIX
Case File Statements
  • DM0000: The mark consists of "MICROBIX" underneath a stylized "M".
  • GS0091: laboratory instruments for the detection pathogens and toxins in a biological sample for research use; Instruments for the processing of cells and cell derived materials, namely, flow cytometers and flow-based analyzers that detect and analyze nucleic acid content for scientific, laboratory, and general research use; laboratory instruments that detect pathogens in a biological sample for research use; Instruments for the processing of cells and cell derived materials
  • GS0051: urokinase used to treat blood clots; Thrombolytic drugs, namely, plasminogen activating drugs and fibrinolytic drugs; urokinase preparations for the restoration of patency to central venous catheters obstructed by clotted blood or fibrin; urokinase preparations for treating pulmonary embolism; urokinase preparations for treating the lysis of acute pulmonary emboli and pulmonary emboli accompanied by unstable hemodynamics; urokinase preparations for treating thrombosis; urokinase preparations for treating coronary artery thrombosis; urokinase preparations for treating myocardial infarction; urokinase preparations for the lysis of thrombi; urokinase preparations for treating peripheral arterial and graft thromboembolic occlusion; urokinase preparations for treating deep vein thrombosis; urokinase preparations for treating pleural effusions; urokinase preparations for treating peripheral arterial occlusion; urokinase preparations for treating ischemic stroke; urokinase preparations for treating lower limb ischemia; test samples used in conjunction with laboratory diagnostics in the nature of biological or biochemical samples used to verify the reliability of laboratory equipment; test samples used in conjunction with assay methods in the nature of biological or biochemical assay samples used to verify the reliability of laboratory tests; Liquid, frozen and lyophilized inactivated, native pathogens, including whole and fragmented eukaryotes, prokaryotes, and viruses, independent and in host cells, all for in vitro and in vivo scientific or diagnostic use; inactivated, native pathogens, namely, liquid, frozen or lyophilized recombinant DNA and/or RNA preparations, either purified or within host organisms, in various buffers, singly and in combination, all for in vitro and in vivo scientific or diagnostic use; Positive controls, namely, reagents for use with nucleic-acid-based, immunologic, or other diagnostic tests to confirm proper test operation, and run in conjunction with patient samples run to confirm, assess, test, or verify the operation of the test method; proficiency test samples in the nature of biological test samples used to test the proficiency of technicians who use infectious disease diagnostics test systems to determine the pathogenic or biochemical content of samples; Diagnostic reagents in the nature of biotechnology products for medical and veterinary use, namely, micro-organisms for amplification controls; Diagnostic kits for in-vitro scientific and diagnostic use; Laboratory assay kits for scientific and diagnostic use; Biological material for scientific or diagnostic purposes, in the nature of serum and plasma from infected and disease state individuals used for verification and validation of human diagnostic assays for such infections and diseases; Biotechnology products for scientific or diagnostic purposes, namely, reagents and solutions in the nature of viruses, bacteria, fungi, parasites, and derivatives thereof used to research, develop, manufacture, and validate infectious disease diagnostic tests; biochemical products, namely, antibodies for scientific or research use; diagnostic reagents containing lyophilized microorganisms, and reagents containing lyophilized microorganisms all for in-vitro use and for use in biochemistry, clinical chemistry and microbiology; diagnostic reagents for scientific research use; diagnostic reagents for medical research use; diagnostic preparations for clinical laboratory use; diagnostic preparations for medical laboratory use; diagnostic preparations for medical research use; diagnostic preparations for scientific research use
  • GS0011: Biochemical agents for in vitro and in vivo scientific or diagnostic use, namely, viruses, bacteria, parasites, and purified and unpurified whole, fragmented, and fractionated pathogens and pathogenic organisms; Cells and cell culture derived products for in vitro or in vivo scientific or diagnostic use, namely, for production of organisms, proteins, nucleic acids, or cellular fractions used as reagents or antigens, test articles, or controls; antibodies and thrombolytics for in vitro scientific or research use; Biochemicals in the form of monoclonal antibodies for in vitro scientific use; Biochemicals in the form of monoclonal antibodies for research use; Active Pharmaceutical Ingredients to stimulate blood-clot dissolving processes; Microbial antigens and antisera for in vitro diagnostic use
  • GS0451: Licensing of process technology used in the manufacturing of vaccines
  • GS0441: Animal husbandry services; animal breeding services; sperm- and semen-sexing services in the nature of in vitro fertilization services; biological cell-selection services for medical purposes in the nature of in vitro fertilization services; medical services in the field of in vitro fertilization, namely, services of delivering energy to a population of biological cells for the purpose of selecting desired cells and negatively selecting undesired cells
  • GS0101: automated flow cytometer sample introduction accessories used in conjunction with a flow cytometer to deliver biological and chemical samples from single test tubes and multiwell laboratory plates; medical apparatus for the automated analysis of cells in the nature of cytometers for medical diagnostic use; medical apparatus for the automated cytometric analysis of cells in the nature of cytometers for medical diagnostic use; medical apparatus in the nature of cytometers that detect atypia in cells for medical diagnostic use; medical apparatus for automated analysis of nuclear features for the detection of neoplasms and cancer and genetic conditions; apparatus for medical diagnostic uses in the nature of an automated flow cytometer sample introduction accessory, namely, a machine which is used in conjunction with a flow cytometer to deliver biological and chemical samples from single test tubes and multi-well laboratory plates
  • GS0421: Providing diagnostic testing services, laboratory tests; production for others of cells, cell lines, viruses, bacteria, and pathogens, proteins, or nucleic acids in whole or in part; Research and development services in the field of process technology used in the manufacture of vaccines; process technology services to be used in the manufacture of a vaccine; biological cell-selection services for biological research purposes; biological research services of delivering energy to a population of biological cells for the purpose of selecting desired cells and negatively selecting undesired cells
Case File Event Statements
  • 10/10/2018 - 6 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/21/2018 - 6 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 6/22/2018 - 6 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 10/4/2018 - 6 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 10/10/2018 - 6 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 10/10/2018 - 6 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 4/10/2019 - 5 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 4/10/2019 - 5 years ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/11/2019 - 5 years ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/24/2019 - 5 years ago
    10 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 4/24/2019 - 5 years ago
    11 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 4/24/2019 - 5 years ago
    12 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 11/15/2019 - 5 years ago
    13 - ASSIGNED TO LIE Type: ALIE
  • 12/4/2019 - 5 years ago
    14 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 12/9/2019 - 5 years ago
    15 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 12/9/2019 - 5 years ago
    16 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 12/9/2019 - 5 years ago
    17 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 6/5/2020 - 4 years ago
    18 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 6/10/2020 - 4 years ago
    19 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 6/10/2020 - 4 years ago
    20 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 6/12/2020 - 4 years ago
    21 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 6/12/2020 - 4 years ago
    22 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 6/12/2020 - 4 years ago
    23 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 3/24/2021 - 3 years ago
    24 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 4/8/2021 - 3 years ago
    25 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 4/8/2021 - 3 years ago
    26 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 4/8/2021 - 3 years ago
    27 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 10/5/2021 - 3 years ago
    28 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 10/12/2021 - 3 years ago
    29 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 10/12/2021 - 3 years ago
    30 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 10/20/2021 - 3 years ago
    31 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 10/20/2021 - 3 years ago
    32 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 10/20/2021 - 3 years ago
    33 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 5/25/2022 - 2 years ago
    34 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 6/9/2022 - 2 years ago
    35 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 6/9/2022 - 2 years ago
    36 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 6/9/2022 - 2 years ago
    37 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 12/12/2022 - 2 years ago
    41 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/5/2022 - 2 years ago
    38 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 12/12/2022 - 2 years ago
    39 - ASSIGNED TO LIE Type: ALIE
  • 12/12/2022 - 2 years ago
    40 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/14/2022 - 2 years ago
    42 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 12/14/2022 - 2 years ago
    43 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 12/14/2022 - 2 years ago
    44 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 7/6/2023 - a year ago
    45 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 7/26/2023 - a year ago
    46 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 7/26/2023 - a year ago
    47 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 7/26/2023 - a year ago
    48 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 10/24/2023 - a year ago
    49 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 10/25/2023 - a year ago
    50 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 10/25/2023 - a year ago
    51 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/28/2023 - a year ago
    52 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 12/28/2023 - a year ago
    53 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 12/28/2023 - a year ago
    54 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 1/30/2024 - a year ago
    55 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 1/30/2024 - a year ago
    56 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/30/2024 - a year ago
    57 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/20/2024 - a year ago
    58 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 2/20/2024 - a year ago
    59 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 2/20/2024 - a year ago
    60 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 2/20/2024 - a year ago
    61 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 2/22/2024 - a year ago
    62 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 3/1/2024 - 12 months ago
    63 - ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Type: ERRR
  • 3/20/2024 - 11 months ago
    64 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 4/9/2024 - 10 months ago
    65 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/9/2024 - 10 months ago
    66 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 6/25/2024 - 8 months ago
    67 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 6/25/2024 - 8 months ago
    68 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC